Hemoglobin A1C Testing Market By Product Type (Instruments {Point-of-Care (POC) Analysers, Bench-top Analysers, Portable Devices}, Reagents and Consumables {Kits, Cartridges}, Testing Services {Laboratory-based Testing, At-home Testing Kits}), By Technology (Ion-Exchange High-Performance Liquid Chromatography (HPLC), Immunoassay, Enzymatic Assay, Electrochemical Detection, Capillary Electrophoresis, Other), By Application (Diabetes Diagnosis, Diabetes Management, Prediabetes Screening, Others), By Distribution Channel (Direct Sales, Retail Pharmacies, Online Channels, Others), By End-User (Hospitals and Clinics, Diagnostic Laboratories, Homecare Settings, Academic and Research Institutes), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles, and Market Forecast, 2024 – 2034

Industry Outlook

The Hemoglobin A1C Testing market accounted for USD 1.63 Billion in 2024 and is expected to reach USD 4.83 Billion by 2035, growing at a CAGR of around 10.37% between 2025 and 2035. The Hemoglobin A1C Testing Market concerns global products related to devices, reagents, and services for testing the measurement of Hemoglobin A1C (HbA1c), which is important for assessing long-term glycemic control. It is particularly important when diagnosing and managing diabetes, as it reports on average glucose levels for 2-3 months. The market includes point-of-care testing devices, laboratory analyzers, and home test kits used by healthcare providers, diagnostic laboratories, and patients. The factors contributing to growth include the incidence of diabetes, raising the level of awareness, and technological development concerning diagnosis and treatment. This is a major tool in health promotion and diabetes prevention worldwide.

Report Scope:

Market Dynamics

Increasing diabetes prevalence continuously drives hemoglobin A1C testing demand.

The increasing prevalence of diabetes worldwide is a strong market influencer in the Hemoglobin A1C Testing Market. As more and more millions of people are diagnosed with diabetes each year, the dependability of monitoring devices has become an issue. It has become customary due to the necessity of monitoring the average blood glucose concentration over several months using hemoglobin A1C tests. Increased cases of diabetes resulting from increased sedentary activities and unhealthy diets bear the additional demand for these tests. The awareness generated through healthcare-related programs that include early detection and constant checkups is also playing a role. This is a clear testament to the role A1C testing holds in helping deal with the burdening effects of diabetes on the global population.

New technologies in the diagnosis of A1C, such as point-of-care devices and home monitoring systems, are hence driving the market forward. These innovations provide faster, more accurate, and more convenient options compared with previous testing options to enable patients with diabetes to easily control that aspect of their health. Health informatics, namely the application of mobile solutions and cloud platforms, enhances the patients’ participation and better governance of diabetes, giving more significance to the use of the A1C test in modern medicine.

Rising awareness about early diagnosis and effective diabetes management

The growing knowledge about the early detection of Type 1 and Type 2 diabetes and the preventive measures are favoring the evolution of the Hemoglobin A1C Testing Market. Due to improved understanding, patients and healthcare workers know how often they ought to get tested to avoid worse outcomes. Hemoglobin A1C tests are well-known to maintain chronic glycemia, which is quite relevant in the case of diabetes treatments. Civil society, professionals, and consumers’ awareness campaigns and sensitization programs have gone a long way in making people appreciate the importance of these tests.

The recent advances in A1C testing include artificial intelligence diagnostic tools and mobile applications, which enable individuals to undergo A1C testing successfully, thereby expanding the range of the population that can afford the same. These developments do not only mean they offer improved speed and efficiency over the results given but also empower patients with their own healthcare decisions. Such a shift towards preventive health care is boosting the uptake of hemoglobin A1C tests to diagnostic status, especially in emerging markets that are transitioning to ambulatory-based healthcare systems in developing nations.

The high cost of advanced testing technologies severely limits their adoption.

The high cost experienced in developed technologies is a major factor that limits the Hemoglobin A1C Testing Market. Current biosensors, equipment, and A1C testing devices in the market are costly and beyond the reach of people within developing and low-income countries. Restricted offers of insurance and reimbursement resources also intensify this problem and discourage its uptake in small health facilities. Due to an increase in the adoption of insurance and cheap treatments in established institutions, patients in underdeveloped areas may be inclined to seek treatment in cheaper markets, hence slowing down the overall market. The cost aspects need to be eliminated through new technologies and an affordable pricing strategy to increase the market reach and accessibility of the A1C testing solutions.

There is low awareness regarding techniques used in the new A1C testing in underdeveloped areas, which causes an aggravated accessibility issue. The lack of a qualified workforce to operate complex instruments and interpret the results hampers the application of the above-mentioned techniques. Although these are the main issues that hinder the expansion of A1C testing in marginalized markets, focused education, development of skills, and easy-to-use testing devices can go a long way in easing the test’s accessibility and, thus, effectiveness.

Emerging Markets Offering Untapped Potential for A1C Testing Opportunities and Growth

High-growth spheres like Asia-Pacific and Africa are prospective markets for the Hemoglobin A1C Testing Market. These areas are retiring and, because of the recent trends towards urbanization and reduction of physical activity, are seeing a rising incidence of diabetes. Also, better healthcare facilities and government awareness programs for the control of diabetes are resulting in enhanced demand for diagnostic equipment. In these areas, raised middle-class people are willing to spend on health care, including periodic A1C tests. Incumbent firms looking to expand into these niche markets in a bid to offer affordable products accompanied by easy access enjoy a wider market share as consumers seek these products.

Telemedicine and digital health solutions improved A1C testing adoption in those areas and are expanding steadily. Apps for health-enabled portable devices and gadgets for consumers are enabling patients to monitor their glucose levels, raising the demand for point-of-care/home testing methods. Other interesting opportunities for the attraction of market participants are the cooperation with regional governments and healthcare providers designed to increase diagnostic access in rural settings.

Advancements in point-of-care testing revolutionizing global market growth

Novel features of point-of-care testing (POCT) are essential in transforming the Hemoglobin A1C Testing Market. POCT device features rapid testing results that can help treat patients on time, thus avoiding frequent visits to the laboratory. These portable devices are uniquely beneficial in regions that are hard to reach and have few or no connections to a central hub facility. To be able to differentiate between accuracy and clinical effectiveness, the following are the advantages of newer generations of POCT devices. These devices are faster in their newer generations; they are more accurate, cheaper, easier to handle, and more acceptable to the patient and the doctor.

Parallel to these enhancements, and as part of the POCT advances, the integration of connectivity features into POCT instruments, such as wireless data transfer and cloud-based monitoring, are revolutionizing the management of diabetes. They enable a fast flow of updated information in the patient-physician feedback loop, enhancing timely clinical and managerial decision-making and individualized/tailored management decisions. Moreover, for these devices, there is less need for complex physical setup, as is the case with other technologies, making it easy to adopt them in low-resource areas, therefore increasing the uptake of the devices across the world.

Industry Experts Opinion

"The demand for accurate and rapid Hemoglobin A1C testing is essential in the global fight against diabetes. Point-of-care devices, in particular, are revolutionizing the landscape by providing faster results with minimal patient discomfort."

            - Dr Emily Parker, PhD in Clinical Diagnostics, University of California

Segment Analysis

Based on the Product Type, the Hemoglobin A1C Testing Market is categorized into Instruments, Reagents and Consumables, and Testing Services. Within the Hemoglobin A1C Testing Market, the Reagents and Consumables segment maintains its dominance as the most important segment. The market segment achieves dominance because users must repeatedly purchase testing kits and cartridges, which meet laboratory and point-of-care testing requirements. Regular monitoring of diabetes cases has led to prolonged product demand because of the increasing diabetic population.

The medical standard for HbA1C testing happens in labs, but point-of-care testing is expanding, which results in additional reagent demand. Technological innovation in reagents both simplifies their testing processes and boosts accuracy levels and operational speed. The broad uptake of quick testing solutions alongside automated systems continues to increase the market for consumables. The market position of this segment is strengthened by the requirement to test patients with diabetes every two to three months.

Based on the Application, the Hemoglobin A1C Testing Market is divided into diabetes diagnosis, diabetes monitoring, and Prediabetes Screening. The diabetes management segment holds the greatest importance in the Hemoglobin A1C Testing Market. To maintain diabetes control, doctors need regular HbA1C testing for blood glucose evaluation, thus enabling proper treatment decisions and minimizing complications. The global rise of diabetes cases requires patients to get periodic tests every two to three months to maintain effective disease control.

The continuous monitoring requirements defined by healthcare guidelines support an increased need for HbA1C tests in both medical facilities and personal homes. Point-of-care devices have gained widespread acceptance because they facilitate more frequent testing procedures, thus improving patient testing compliance. Automated analyzer development enhances segment efficiency to a greater extent. Diabetes care plans have evolved in a way that requires HbA1C testing to become the lead diagnostic parameter in disease control initiatives.

Regional Analysis

The North American Hemoglobin A1C Testing Market shows growth because diabetes has become more common among populations throughout the United States and Canada. The National Diabetes Prevention Program from the CDC has received government support to detect diabetes early, which results in increased test use among patients. The market benefits from technological improvements that offer point-of-care (POC) testing devices to enhance both accessibility and efficiency levels. Healthcare facilities throughout this region benefit from extensive insurance coverage that enables A1C testing reimbursement. Search for diagnostic tests continues to expand through laboratory facilities and homeowner options because customers want convenient testing possibilities. High-quality standards for A1C tests are secured through regulatory approvals from the FDA and similar agencies. The market growth gets strengthened through diagnostic companies existing in the sector, while continued awareness about diabetes management leads patients to perform regular testing. Healthcare providers working together with diagnostic companies enhance the availability of tests.

The Asia Pacific Hemoglobin A1C Testing Market shows expanding growth because of increasing diabetes cases, which are prominent in China, India, and Japan. The Indian government operates the National Programme for Prevention and Control of Diabetes, which supports early diagnosis efforts that drive test adoption. Market expansion receives support from expanding healthcare facilities combined with the development of diagnostic laboratories. The healthcare industry experiences growing acceptance of point-of-care testing solutions throughout rural areas that possess limited healthcare services.

National regulations determine how available and priced testing measures are throughout different countries. The rising numbers of elderly people and modern lifestyle patterns drive up the market need for A1C testing. Market expansion receives additional support from the increased coverage of medical insurance and investments made by private healthcare organizations. Diabetes management receives a boost through health organizations that spread awareness, leading people to practice regular monitoring. The efficiency of testing processes is improved through automated analyzers developed via technological innovation. Regional healthcare providers who collaborate with international diagnostic firms help expand their business presence across markets.

 Competitive Landscape

Competing actors in the Hemoglobin A1C Testing Market use their advanced diagnostic solutions to face intense commercial competition. The companies Abbott and Siemens Healthineers AG, along with Danaher, use their robust research and development platforms to create efficient HbA1c testing solutions with better accuracy levels. Bio-Rad Laboratories, Inc., together with ARKRAY, Inc., produces laboratory-based analyzers, but HemoCue AB with Nova Biomedical concentrates on providing point-of-care (POC) devices that deliver quick results.

The HbA1c testing capabilities from Medtronic exist within their diabetes management systems as the company challenges AliveDx and PTS Diagnostics through their portable compact testing devices. The market expansion of Tosoh India Pvt. Ltd. and Diazyme Laboratories depends on their innovative reagent development. Trinity Biotech and Sebia utilize electrophoresis-based techniques in their product lines along with QuidelOrtho Corporation and Thermo Fisher Scientific Inc., which sell broadly applicable diagnostic products to achieve market penetration. Menarini Diagnostics s.r.l. Targets European expansion with strategic collaborations. The competitive industry exists because of technical improvements alongside certification authorizations coupled with growing demand for diabetes monitoring technology.

Hemoglobin A1C Testing Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In December 2023, Siemens Healthineers launched a new version of its DCA Vantage® Analyzer, intended to improve the effectiveness as well as the usability of HbA1c testing. The enhancements in the new analyzer include an output time that is shorter than 5 minutes; now, it only takes 3 minutes. In this innovation, the hope is to enhance point-of-care diabetes management, enabling healthcare providers to provide timely changes to the therapy plan for diabetic patients.
• In October 2023, Roche Diagnostics introduced an advanced version of its Cobas® b 101 analyzer to assess HbA1c. This version allows the device to provide accurate and fast results and improve usability in outpatient clinics. The new system aims to decrease patient waiting time while giving healthcare professionals the necessary tools to address the management of diabetes due to an increase in demand for better, faster, and more accurate diagnostics.

Report Coverage:

By Product Type

• Instruments
  • Point-of-Care (POC) Analysers
  • Bench-top Analysers
  • Portable Devices
• Reagents and Consumables
  • Kits
  • Cartridges
• Testing Services
  • Laboratory-based Testing
  • At-home Testing Kits

By Technology

• Ion-Exchange High-Performance Liquid Chromatography (HPLC)
• Immunoassay
• Enzymatic Assay
• Electrochemical Detection
• Capillary Electrophoresis
• Other

 By Application

• Diabetes Diagnosis
• Diabetes Management
• Prediabetes Screening
• Other

By Distribution Channel

• Direct Sales
• Retail Pharmacies
• Online Channels
• Others

By End-User

• Hospitals and Clinics
• Diagnostic Laboratories
• Homecare Settings
• Academic and Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Abbott
• Siemens Healthineers AG
• Danaher
• Bio-Rad Laboratories, Inc.
• ARKRAY, Inc.
• Tosoh India Pvt. Ltd
• Trinity Biotech
• Diazyme Laboratories
• PTS Diagnostics     
• EKF Diagnostics Holdings plc.
• Sebia
• HemoCue AB
• Medtronic
• AliveDx
• Nova Biomedical 
• QuidelOrtho Corporation
• Thermo Fisher Scientific Inc.
• Menarini Diagnostics s.r.l 

Frequently Asked Questions (FAQs)